

**Curriculum Vitae**  
**André K. D. Liem, M.D.**

---

**Office:** Pacific Shores Medical Group

1043 Elm Avenue, Ste. 104  
Long Beach, CA 90813

**Professional Accreditation**

May, 2004 Recertification, Internal Medicine, Diplomate American Board of Internal Medicine (157574)  
Aug 97 Hematology, Diplomate, American Board of Internal Medicine (157574)  
Aug 97 Medical Oncology Diplomate, American Board of Internal Medicine  
Aug 94 Internal Medicine, Diplomate American Board of Internal Medicine  
July 31, 91 Educational Commission for Foreign Medical Graduates (457-327-5)  
June 91 Federal Licensing Examination (610225010)  
April 10, 87 M.D., Radboud University Nijmegen, The Netherlands  
March 85 M.Sc. Medicine, Radboud University Nijmegen, The Netherlands

**Licenses**

June 8, 94 Medical board of California (A053159)  
Aug 13, 93 Medical license Connecticut (033237) (inactive)

**Postgraduate Training**

July 94 – July 97 Hematology & Oncology Fellowship Program  
University of California at Irvine Medical Center, Orange, California  
July 91 - July 94 Internal Medicine Residency Program  
University of Connecticut Health Center, Farmington, Connecticut  
Feb 90 - Sep 90 Emergency Medicine Senior House Officer  
Charing Cross Hospital, London, United Kingdom.  
Aug 89 - Jan 90 Internal Medicine Internship  
Luton & Dunstable Hospital, Luton, United Kingdom  
Aug 88 - Jan 89 Surgical Internship (General Surgery & Urology)  
St. Mary's Hospital, Portsmouth, United Kingdom

**Work Experience**

Sep 99- present Pacific Shores Medical Group  
Medical Oncology Practice  
Sep 97- Sep 99 Coast Hematology Oncology Associates, Long Beach, California  
Medical Oncology Practice  
May 96- Sep 97 Sunrise Medical Group, Orange, California  
Urgent Care Clinic  
Feb 89 - July 89 Locum tenens in Internal Medicine and Surgery, United Kingdom

**Curriculum Vitae**  
**André K. D. Liem, M.D.**

---

**Professional Development**

- Sept 93 - Oct 93     Adult and Pediatric Bone Marrow Transplant Unit  
Fred Hutchinson Cancer Research Center, Seattle, Washington
- June 87 - June 88     Medical Biology  
Radboud University Nijmegen, The Netherlands
- Accredited in applied statistics, immunology, computer programming, clinical and immuno-toxicology

**Research**

- 2005- present     Principal investigator UCLA Affiliated Translational Oncology Research Network
- 2005     Principal investigator Z-MAX CZOL446EUS97  
A Multicenter, Open-Label, Randomized trial evaluating the duration of infusion of ZOMETA® (zoledronic acid) 4 mg IV in Multiple Myeloma Patients with Bone Metastases
- 2005     Principal investigator BMS CA225006  
A phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs Irinotecan as Second-Line Treatment in Patients with metastatic, EGFR-Positive Colorectal Carcinoma
- 2005     Principal investigator AMG 162 20040114  
A Randomized, Active Controlled Study of AMG 162 in Subjects with Advanced Cancer Currently Being Treated with Intravenous Bisphosphonates
- 2005     Principal investigator TORI B-01  
A Randomized Phase II Trial of Docetaxel With or Without Bevacizumab as First-Line Therapy for HER2-Negative Metastatic Breast Cancer
- 2005     Principal investigator BO17920  
A randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma
- 2005     Principal investigator PR04-27-018  
Assessment of Early and Standard Intervention with PROCRT® (Epoetin alfa) 120,000 Units Once Every Three weeks (Q3W) in Patients with Cancer Receiving Chemotherapy
- 2004     Principal investigator OSI2950g  
A Phase II, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Avastin™ (Bevacizumab) in combination with Docetaxel or Tarceva™ (Erlotinib Hydrochloride) Compared with Docetaxel alone for Treatment of Recurrent or Refractory Non-Small Cell Lung Cancer

**Curriculum Vitae**  
**André K. D. Liem, M.D.**

---

- Jan 96 - June 96      Moloney Murine Leukemia Virus Ribozyme  
University of California at Irvine, California
- Nov 87 - Dec 87      Parasited Erythrocytes and Immunogenic Parasited Erythrocytes in  
Plasmodium bergeri.  
Radboud University Nijmegen, The Netherlands
- Aug 87 - Sep 87      Characterization of Glutamate Dehydrogenase and Ammonia in Bacillus  
fastidiosus.  
Radboud University Nijmegen, The Netherlands
- Oct 85 - Dec 85      T-cell receptor rearrangements in Mycosis Fungoides and Sézary  
Syndrome.  
British Columbia Cancer Research Centre, Vancouver, British Columbia,  
Canada

**Publications**

- June 1989              Purification and characterization of the NADP-dependent glutamate  
dehydrogenase from Bacillus fastidiosus. Antonie van Leeuwenhoek  
55:303-311 (1989)
- May 2002              Liem AK, Cheng H, Quan E, Ucar K, Al-Jazayrly G, Barton C, Cloo L,  
Gabert T, Tchekmedyian S: Expanded access single institution clinical  
program experience with ZD1839 (Iressa <sup>TM</sup>) for patients with advanced  
non-small cell lung cancer (NSCLC). proc. of the american society of  
clinical oncology, Abstr. #2705, 2002.
- November 2002        Tchekmedyian NS, Liem AKD: A Patient with Metastatic Non-Small-  
Cell Lung Cancer Treated with ZD1839. CASE STUDIES IN LONG  
CANCER, a Physicians' Education Resource publication, vol.1, no. 9,  
November 2002.

7/20/05

Dr. Liem CV July 20 2005.doc